Yokneam Illit

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $9.6 million in 10 new projects: The approved projects, with an overall budget of $24.5 million, involve innovations in the areas of Agrotech, Biotechnology, Electronics, Energy, Foodtech,

Retrieved on: 
Wednesday, January 31, 2024
Misgav, MD, BIRD Foundation, Commerce, BIRD, Planner, Associate, Partnership, Yokneam Illit, Mayo Clinic, History, TEL, Carbon, Splenic infarction, Lod, Intelligence, Sheba Medical Center, Patient, Ministry, Mondelez International, NIST, Approval, Virtual reality, Anopheles, Agriculture, Anopheles stephensi, Parity, Rehovot, ATCC, Hope, Malaria, Pharmaceutical industry

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • In addition to providing conditional grants of up to $1.5 million, the Foundation assists by working with companies to identify potential strategic partners and facilitate introductions.
  • The ten projects approved by the Board of Governors are in addition to the over 1000 projects that the BIRD Foundation has approved for funding during its 46-year history.

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $8 million in 9 new projects: The approved projects, with an overall budget of $23 million, involve innovations in the areas of Agrotech, Biotech, Electronics, Foodtech, Medical Devices, an

Retrieved on: 
Wednesday, July 26, 2023
NIST, DSM-IV codes, DNA, Food, Rehovot, Photonic integrated circuit, U.S. Department of Defense Strategy for Operating in Cyberspace, Adventist HealthCare, BIRD Foundation, Yokneam Illit, Food safety, Blinking, RNA, History, The Toro Company, Ministry, TEL, Israel Innovation Authority, National Institute of Standards and Technology, Commerce, Investment, Florida Board of Governors, Diagnosis, BIRD, Quantum machine learning, Paralysis, U.S. Department of Commerce Office of Security, Pharmaceutical industry, Medical device, Creative industries, Science, Innovation, Herzliya

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $23 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $23 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • The nine projects approved by the Board of Governors are in addition to over 1000 projects which the BIRD Foundation has approved for funding during its 46-year history.
  • To date, BIRD's total investment in joint projects is over $390 million, helping to generate direct and indirect sales of more than $10 billion.

Wearable Devices to Present at Investor Summit Group's Q4 Conference

Retrieved on: 
Tuesday, November 8, 2022
Sheraton New York Times Square Hotel, Science and technology in Asia, Yokneam Illit, Complimentary, Technology, Artificial intelligence, Seventh Avenue, Wrist, NASDAQ, Company, Algorithm, WLDS, Mobile phone, Metaverse

Yokneam Illit, Israel--(Newsfile Corp. - November 8, 2022) - Wearable Devices (NASDAQ: WLDS) today announced that management will attend the Q4 Investor Summit at the Sheraton Times Square in New York City on Monday, November 14, 2022.

Key Points: 
  • Yokneam Illit, Israel--(Newsfile Corp. - November 8, 2022) - Wearable Devices (NASDAQ: WLDS) today announced that management will attend the Q4 Investor Summit at the Sheraton Times Square in New York City on Monday, November 14, 2022.
  • Asher Dahan, Chief Executive Officer of Wearable Devices Ltd., will give a company presentation at 12:00 p.m.
  • Interested investors can view the presentation live at this link and a replay of the presentation will also be available.
  • Please register at Complimentary Investor Registration
    Wearable Devices Ltd. (the "Company"), a growth company developing a non-invasive neural input interface technology in the form of a wrist wearable band for controlling digital devices using subtle finger movements.

DGAP-News: NextFerm Technologies announces a strategic manufacturing agreement for the production of ProteVin™, its vegan protein, with a subcontractor in Europe

Retrieved on: 
Thursday, September 8, 2022
Milk, Food, Yokneam Illit, Research, Achievement, USD, Publishing, Infant, Tel Aviv Stock Exchange, Company, GMO, Meat, Adult, IP, TASE, Environment, Marketing, Fine chemical, Dietary supplement, Lallemant

NextFerm Technologies announces a strategic manufacturing agreement for the production of ProteVin, its vegan protein, with a subcontractor in Europe

Key Points: 
  • NextFerm Technologies announces a strategic manufacturing agreement for the production of ProteVin, its vegan protein, with a subcontractor in Europe
    The issuer is solely responsible for the content of this announcement.
  • This marks the achievement of the companys third strategic milestone (out of five) set for 2022.
  • According to the agreement, the manufacturing plant will enable, at first stage, the production of ProteVin with an annual capacity of up to $10M starting the second half of 2023.
  • The subcontractor will establish the plant and will provide the production services as well as the bakers yeast necessary to produce ProteVin.

DGAP-News: NextFerm Technologies announces a $3 million Supply agreement for its vegan protein: ProteVin™

Retrieved on: 
Tuesday, August 16, 2022
Tel Aviv Stock Exchange, Protein, Industry, USD, GMO, Research, Meat, Environment, Founder, Marketing, Company, Food, Milk, Infant, Yokneam Illit, Goal, Ethics, TASE, Publishing, Dietary supplement, Adult, Beer, Lallemant

NextFerm Technologies announces a $3 million Supply agreement for its vegan protein: ProteVin

Key Points: 
  • NextFerm Technologies announces a $3 million Supply agreement for its vegan protein: ProteVin
    The issuer is solely responsible for the content of this announcement.
  • This agreement includes the initial supply of protein in the amount of few tons carried out in June 2022.
  • The agreement stipulates that Spacemilk will promote the ProteVin brand on the product packaging, as it is the dominant nutritional component underlying the product.
  • Boaz Noy, Chief Executive Officer of NextFerm, said: "We are pleased to announce the first multi-year supply agreement for ProteVin.

DGAP-News: NextFerm Technologies announces its first commercial delivery of ProteVin™, in the U.S

Retrieved on: 
Wednesday, June 22, 2022
Infant, Environment, Achievement, Publishing, GMO, Yokneam Illit, Company, Snack, Research, TASE, Growth, USD, Marketing, Milk, Health, Meat, Food, Adult, Tel Aviv Stock Exchange, Sale, Former, Dietary supplement, Beer, Lallemant

SpaceMilk (Former PrimaLife Nutrition), is a US health and wellness brand and the first to launch a vegan protein powder based on ProteVin.

Key Points: 
  • SpaceMilk (Former PrimaLife Nutrition), is a US health and wellness brand and the first to launch a vegan protein powder based on ProteVin.
  • This protein powder will enable consumers to enjoy vegan protein with animal like nutritional value and perfect taste.
  • SpaceMilk is expected to be launched and available for sale to end users during the coming summer months, mostly online.
  • The supply of the remaining of the order, as well as other open orders, shall continue during the coming weeks.

PixCell Medical Appoints Armin Schon as New Chief Commercial Officer to Foster Continued HemoScreen™ Growth

Retrieved on: 
Thursday, July 15, 2021
Economy of Israel, Science and technology in Israel, Yokneam Illit, Yokneam, Israel, Archaeological sites

YOKNEAM ILLIT, Israel, July 15, 2021 /PRNewswire/ -- PixCell Medical , innovator of rapid diagnostic solutions at the point-of-care, announced today that Armin Schon, Ph.D., has been appointed chief commercial officer, effective immediately.

Key Points: 
  • YOKNEAM ILLIT, Israel, July 15, 2021 /PRNewswire/ -- PixCell Medical , innovator of rapid diagnostic solutions at the point-of-care, announced today that Armin Schon, Ph.D., has been appointed chief commercial officer, effective immediately.
  • Schon will oversee PixCell's global commercial partnerships, all sales and marketing activities and distribution of the company's proprietary hematology analyzer, HemoScreen.
  • "As a member of PixCell's board, I helped the company progress to the commercial product we now know as HemoScreen.
  • Schon brings more than 20 years of multidisciplinary experience in strategy and business development for global science-based industries and medical device companies.